GlassScriptPhysician profile
Daniel R Shumpert
NPI 1891082640
$1,976.78
in general payments reported to CMS, 2019-2025
27 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $86.21 · 2022: $148 · 2023: $415 · 2024: $489 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $461.89 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $221.88 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $155.08 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $137.52 | 2019-2025 | Evenity, Prolia, Prolia |
| Exact Sciences Corporation | $133.80 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $132.71 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.25 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $95.83 | 2023-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $63.43 | 2019 | |
| Astellas Pharma US INC | $53.68 | 2019-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $52.65 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.60 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $35.01 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Shield Therapeutics INC | $31.31 | 2025 | |
| Idorsia Pharmaceuticals US INC | $30.75 | 2022-2024 | Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $25.93 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $24.80 | 2019 | |
| Abbott Laboratories | $24.49 | 2024 | Freestyle Libre 3 |
| Jazz Pharmaceuticals INC. | $23.84 | 2019 | |
| Cvrx, INC. | $19.58 | 2025 | Barostim Neo System |
| Alexion Pharmaceuticals, INC. | $16.70 | 2023 | Strensiq |
| Xeris Pharmaceuticals, INC. | $16.28 | 2024 | Gvoke Hypopen |
| Aytu Biopharma, INC. | $15.22 | 2019 | |
| Corcept Therapeutics | $14.04 | 2024 | Korlym |
| Zyla Life Sciences, INC. | $12.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.21 | 2019 | |
| Bausch Health US, LLC | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Shumpert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.